Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone

Journal of Infectious Diseases

Volumn 186, Issue 8, 2002, Pages 1065-1073

  Meseda, Clement A ^a   Elkins, Karen L ^a   Merchlinsky, Michael J ^a   Weir, Jerry P ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN D; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA VECTOR; SPLEEN CELL; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, VIRAL; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINATION; VACCINES, DNA; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 0037108985     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344234     Document Type: Article

References (35)

1. Manickan E, Rouse RJD, Yu Z, Wire WS, Rouse BT. Genetic immunization against herpes simplex virus. J Immunol 1995;155:259-65
2. Manickan E, Yu Z, Rouse RJD, Wire WS, Rouse BT. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate-early protein ICP27. Viral Immunol 1995;8:53-61.
3. Ghiasi H, Cai S, Slanina S, Nesburn AB, Wechsler SL. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-2 challenge. Antiviral Res 1995;28:147-57.
4. Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996;173:800-7.
5. Kriesel JD, Spruance SL, Daynes RA, Araneo BA. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease. J Infect Dis 1996;173:536-41.
6. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996;93:11414-20.
7. Nass PH, Elkins KL, Weir JP. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. J Infect Dis 1998;178:611-7.
8. Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine 1999;18:875-83.
9. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999;17:1681-9.
10. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000;30:549-66.
11. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-48.
12. Ramsay AJ, Kent SJ, Strugnell RA, Suhrbier A, Thomson SA, Ramshaw IA. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev 1999;171:27-44.
13. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000;21:163-5.
14. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein. Science 2001;292:69-74.
15. Robinson HL, Montefiori DC, Johnson RP. et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999;5:526-34.
16. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998;79:1159-67.
17. Ausubel FM, Brent R, Kingston RE, et al. Current protocols in molecular biology. New York: Greene and Wiley, 1987.
18. Denniston KJ, Madden MJ, Enquist LW, Vande Woude G. Characterization of coliphage lambda hybrids carrying DNA fragments from herpes simplex virus type 1 defective interfering particles. Gene 1981;15:365-78.
19. Ourmanov I, Brown CR, Moss B, et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000;74:2740-51.
20. Pachl C, Burke RL, Stuve LL, et al. Expression of cell associated and secreted forms of herpes simplex virus type 1 glycoprotein gB in mammalian cells. J Virol 1987;61:315-25.
21. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999;282:331-40.
22. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
23. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343:1460-3.
24. Sin JI, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999;73:501-9.
25. + T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999;170:29-38.
26. Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism [in German]. Zentralbl Bakteriol B 1978;167:375-90.
27. Sin JI, Bagarazzi M, Pachuk C, Weiner DB. DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model. DNA Cell Biol 1999;18:771-9.
28. Eo SK, Gierynska M, Kamar AA, Rouse BT. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 2001;166:5473-9.
29. Stittelaar KJ, Kuiken T, de Swart RL, et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001;19:3700-9.
30. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000;74:923-33.
31. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000;74:7651-5.
32. Yoshida A, Nagata T, Uchijima M, Higashi T, Koide Y. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine 2000;18:1725-9.
33. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-82.
34. Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996;70:6119-25.
35. Degano P, Schneider J, Hannan CM, Gilbert SC, Hill AV. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999; 18:623-32